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THE  DETECTION OF A  SPLEEN FOCUS-FORMING VIRUS 
NEOANTIGEN BY LYMPHOCYTE-MEDIATED CYTOLYSIS* 
BY STEVEN  GILLIS, ANNE  E. GILLIS, AND KENDALL  A. SMITH 
(From the  Department  of  Medicine,  Dartmouth-Hitchcock Medical Center,  Hanover, New 
Hampshire 03 755) 
Murine erythroleukemia  cells induced by Friend (FLV) 1 and Rauscher (RLV) 
leukemia viruses have been shown to  express tumor-associated cell surface 
antigens (TASA) (1-3). The genes coding for these antigens have remained ill- 
defined, although present evidence indicates that the helper virus (lymphatic 
leukemia virus, LLV) genome may be responsible (4-6). 
Until recently, it was not possible to examine putative cell surface antigens 
coded for by the replication-defective  portion (spleen focus-forming  virus, SFFV) 
of the viral genome due to an excess of helper LLV present in viral isolates. 
Troxler et al. (7) as well as Bernstein et al. (8) have recently obtained the SFFV 
genome free of LLV in both murine and rat cell lines through virus and cell 
cloning procedures. These developments have permitted the investigation of 
possible  cell surface antigens contributed by genetic information contained in 
SFFV. 
We  have  applied  the  techniques  of  secondary  mixed  tumor-lymphocyte 
culture (MTLC) stimulation followed by lymphocyte-mediated  cytolysis (LMC) 
assays (tests used to demonstrate immunity inthe murine sarcoma virus, MSV, 
system [9, 10]) to this SFFV nonproducer model system to investigate whether 
or not the SFFV genome alone codes for a cell surface antigen. We now report 
that BALB/c 3T3 clones containing the SFFV genome free of infectious LLV, 
express a cell surface antigen which is not a virus structural protein, yet which 
is present on the surfaces of syngeneic, productively infected RLV and FLV- 
induced erythroleukemia  cells. 
Materials and Methods 
Mice.  Age-matched BALB/c female,  8-10-wk-old  mice were  used  in  immunization experi- 
ments and as sources for normal thymocytes in LMC assays.  All mice were obtained from The 
Jackson Laboratory, Bar Harbor, Maine. 
* Supported in part by a  research grant  (CA 17643) and a research contract (N01-CB-74141) 
from the National Cancer Institute. 
1  Abbreviations  used in this paper:  C, core; E, envelope; FCS, fetal calf serum; FeLV, feline 
leukemia  virus;  FLV,  Friend  leukemia  virus;  FOCMA,  feline  oncornavirus-associated  cell 
membrane antigen; GCSA, Gross cell surface antigen; GLV, Gross leukemia virus; gp, glycopro- 
tein; KiSV, Kirsten sarcoma virus; LLV, lymphatic leukemia virus; LMC, lymphocyte-mediated 
cytolysis; LU, lytic unit;  MCSA,  Moloney  cell surface  antigen; Mo-MuLV,  Moloney leukemia 
virus; MSV,  murine sarcoma virus; MTLC,  mixed tumor-lymphocyte culture;  MuLV,  murine 
leukemia virus; p, protein; PFU, plaque-forming units; RIA, radioimmunoassay; RLV, Rauscher 
leukemia  virus;  RT,  reverse transcriptase;  SFFV,  spleen focus-forming virus; TASA, tumor- 
associated cell surface antigen. 
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Target Cells.  Two nontransformed, nonproducer BALB/c 3T3 fibroblast cell lines containing 
the SFFV genome and free of replicating LLV (1902 B CI-4 and 1902 B C1-6) were obtained from 
Dr. David H. Troxler, Laboratory of Tumor Virus Genetics, National Cancer Institute, Bethesda, 
Md. (7). 
Dr. Troxler also provided the parent BALB/c 3T3 cell line from which the SFFV nonpreducers 
were cloned; a BALB/c 3T3 cell line productively infected with a cloned Friend LLV (BALB/c 3T3 
F-murine leukemia virus [MuLV]); the 1902 B C1-1 cell line (a normal BALB/c 3T3 cell line cloned 
in the same experiment which successfully isolated the SFFV nonproducer clones); the SFFV- 
FRE  cell line  (11);  a  Fischer rat epithelial cell which also contains the SFFV genome free of 
replicating LLV; and the FRE cell line, a  Fischer rat epithelial cell which lacks SFFV genetic 
information.  Other  target  cells  syngeneic  to  the  BALB/c  mouse  included  the  RLV-induced, 
MCDV-12 leukemia cell (obtained from Dr.  Ronald Herberman, National Cancer Institute) and 
the  FLV-induced,  FLD-3  erythroleukemia  cell  (obtained  from  Dr.  W.  Ostertag,  Max  Planck 
Institute, GSttingen, W. Germany). 
The 1902 B C1-4 cell line was productively infected with two LLV preparations resulting in the 
generation of two additional target ceils. 1902 B C1-4-R-MuLV was produced by the co-cultivation 
of the 1902  B  C1-4 cell with TNF leukemia cells.  The TNF cell line was initiated by Dr.  T.  N. 
Fredrickson et al.  (12)  from a  leukemic mouse injected with an end-point diluted stock of RLV. 
The TNF cell line was adapted to tissue culture in our laboratory and produces RNA tumor virus 
as measured by XC (2,002 plaque-forming units [PFU]/ml) and reverse transcriptase (RT) assays. 
However, TNF tissue culture fluid lacks in vivo SFFV activity (20,000 XC PFU failed to produce 
spleen loci, data per Dr.  Richard Steeves,  Albert Einstein College of Medicine, Bronx,  N.  Y.). 
1902 B C1-4-Moloney leukemia virus (Mo-MuLV) was produced by the co-cultivation of 1902 B C1- 
4 cells with MBL-2 leukemia cells. The MBL-2 is an Mo-MuLV-transformed tumor cell syngeneic 
to the C57B1/6  mouse which produces large amounts of MuLV as detected in XC (5,200 PFU/ml) 
and RT assays. 
BALB/c 3T3 cells were also productively infected with R-MuLV and Mo-MuLV by co-cultivation 
with TNF and MBL-2 leukemia cells, respectively. These co-cultivations resulted in the genera- 
tion  of two  nontransformed,  LLV-producing  fibroblast  cell  lines;  BALB/c  3T3-R-MuLV  and 
BALB/c  3T3-Mo-MuLV.  The  Kirsten  sarcoma  virus  (KiSV)-transformed,  replication-defective 
BALB/c  3T3  cell  line  (K-BALB;  13)  was  obtained  from  Dr.  Robert  Bassin,  National  Cancer 
Institute. The sarcoma virus genome of this transformed cell was also rescued by co-cultivation 
with TNF and MBL-2 leukemia cells resulting in the production of two KiSV-rescued cell lines; 
K-BALB-R-MuLV and K-BALB-Mo-MuLV. 
Fibroblast cell lines were maintained in Dulbecco's modified Eagle's medium  (Grand Island 
Biological Co.,  Grand Island,  N.  Y.) supplemented with 10%  heat-inactivated fetal calf serum 
(FCS; Grand Island Biological Co.), 50 U/ml penicillin, 50/zg/ml gentamicin, and 300 ~g/ml fresh 
L-glutamine  (Grand Island Biological Co.).  MBL-2,  TNF,  FLD-3,  and MCDV-12  leukemia cells 
were maintained in suspension culture in RPMI-1640 (Grand Island Biological Co.) supplemented 
with 10% FCS, 2.5 x  10 -5 M beta-mercaptoethanol/ml, 50 #g/mt gentamicin, and 300/zg/ml fresh 
L-glutamine. All cells were cultured in a  humidified atmosphere of 5% CO2 in air at 37°C. 
Immunization.  Mice were immunized subcutaneously in the right flank with I  ×  10  s live 1902 
B  C1-4 SFFV nonproducer cells biweekly for a  period of 6 wk.  Spleen and inguinal lymph node 
cells were used as responding lymphocytes in in vitro activation with 1902 B C1-4 cells,  2-12 wk 
after completion of the immunization schedule. 
Viral Characterization of Target Cells.  Tests for RT activity (14) present in target cell tissue 
culture medium, and for production of mature MuLV (XC assay; 15) were conducted as previously 
described.  As a  more sensitive indicator of MuLV production in XC assays,  1  ×  104 target cells 
were olden co-cultivated with SC-1 cells for 4 days before the addition of the XC rat indicator cell. 
Target cells used  in LMC  assays were  tested for the presence of cell surface  viral proteins in 
antibody-dependent, complement-mediated cytolysis assays.  Heat-inactivated,  absorbed,  mono- 
specific goat antisera raised against purified murine ecotropic and xenotrepic viral proteins were 
tested  (obtained  from  Dr.  Jack  Gruber,  Office  of  Program  Resources  and  Logistics,  Viral 
Oncology, National Cancer Institute). The antigenic specificity of all antisera used in these tests 
as defined by Dr. Gruber is detailed in Table I. Methods involved in antibody-dependent comple- 
ment-mediated cytolysis assays have been previously described (10). 
7-day  assays  for  MSV  production  on  SC-1  mouse  fibroblasts,  using  target  tissue  culture 
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TABLE  I 
Specificity  of  Antisera Used in Antibody-Dependent Complement-Mediated Cytolysis 
Assays for Cell Surface Expression  of Viral Structural Proteins 
Goat antisera  Preparation of  immu-  Radioimmunoassay specificity  data  labeled antigen 
anti -  nizing antigen  (50% binding titer)* 
AKR  MuLV  Ion  exchange  chroma- 
pl0  tography & gel filtra- 
tion 
AKR  MuLV  Ion  exchange  chromo- 
p30  tagraphy & gel filtra- 
tion 
BALB virus 2  Guanidine  HC1  +  aga- 
pl0  rose chromatography 
BALB virus 3  Guanidine  HC1  +  aga- 
p30  rose chromotography 
BALB virus  2  Ion  exchange  chroma- 
gp69/71  tography 
GLVpl2  Ion  exchange  chroma- 
tography 
GLVp30  Ion  exchange  chroma- 
tography 
RLV pl0  Guanidine  HC1  +  aga- 
rose chromatography 
RLV p12  Guanidine  HC1  +  aga- 
rose chromatography 
RLV pl5  Guanidine  HC1  +  aga- 
rose chromatography 
RLV p30  Guanidine  HC1  +  aga- 
rose chromatography 
RLV  p60  pre-  Guanidine  HC1  +  aga- 
cursor  rose chromatography 
RLVgp69/71  Ion  exchange  chroma- 
tography 
AKR MuLV pl0(150),  RLV p30(<50),  AKR MuLV 
p12(<50) 
AKR MuLV p30(800), RLV p30(24,000), AKR MuLV 
pl0(<50), AKR MuLV p12 (<50) 
BALB virus 2 p10(2720),BALB virus 2 p30(<50) 
BALB virus 2 p30 (1000) 
BALB virus 2 gp69/71(9600), BALB virus 2 p30(<50) 
GLV p12(4800), GLV p30(<50) 
GLV p30(9800) 
RLV p10(9600), RLV p30(<50) 
RLV p12(18,000),  RLV gp69/71(<50),  RLV p30(75) 
RLV p10(9600) 
RLV p15(2000), RLV p30(50) 
RLV p30(38,000) 
ND$ 
RLV gp69/71(3200), RLV p30(<50) 
* Expressed as  reciprocal  of  serum dilution  corresponding to  50% binding titer  of  labeled antigen. 
ND, not  done. 
tested for xenotropic virus production on mink lung fibroblast cells as measured by insipient RT 
activity (17). ATS-Dog and NZB-Dog cell tissue culture fluid was used as a positive control in all 
assays for xenotropic virus production (cells obtained from Dr. Sandra K. Ruscetti, Laboratory of 
Tumor  Virus  Genetics,  National  Cancer  Institute).  24-h  tissue  culture  fluid  harvested  from 
cultures of SFFV nonpreducer and nonpreducer-rescued cell lines were assayed for in vivo SFFV 
activity by  inoculation into CDF1 newborn  mice.  Assays  for in  vivo SFFV activity (18) were 
conducted  by Dr. Richard Steeves. 
In Vitro Activation of 1902 B Cl-4-Immune Lymphocytes.  Spleen and inguinal lymph node 
cells from immunized mice were teased apart from the intact organ with forceps,  minced, and 
passed through successively smaller gauge needles to insure single cell suspension. Erythrocytes 
were removed from the cell population by hyposmotic shock, and the remaining cells were counted 
with a Coulter electronic counter (Coulter Electronics Inc., Hialeah, Fla.). A£cer  we determined 
cell viability via trypan blue exclusion, we diluted cells in Click's medium (Altick Associates, 
Hudson, Wis.),  supplemented with 2% FCS, 300 ~g/ml fresh L-glutamine, 50 U/ml penicillin, 50 
~g/ml gentamicin, 16 ~mol/ml NaHCO3,  and 25 ~mol/ml Hepes buffer (Calbiochem, San Diego, 
Calif.).  Spleen cell populations were adjusted to a final concentration of 2.5 x l0  s cells/ml. In vitro 
activation of 1902 B C1-4 immune lymphocytes was conducted by mixing 10 ml of spleen cells with 
10 ml of UV-irradiated (6,000 electroretinograms/mm  =)  1902 B C1-4 flbroblasts which had been 
adjusted  in  supplemented  Click's medium  to  a  concentration of 1.25  x  l0  s cells/ml. In  vitro STEVEN  GILLIS,  ANNE  E.  GILLIS,  AND  KENDALL  A.  SMITH  21 
lymphocyte activations were conducted in 30-ml tissue culture flasks (3012; Falcon Plastics, Div. 
of BioQuest,  Oxnard,  Calif.) cultured upright in a  humidified atmosphere of 5% CO2 in air at 
37°C. Activated lymphocytes were harvested after 5 days in culture, and viable cells were used as 
effector cells in LMC assays. 
LMC Assays.  4-h 5~Cr-release assays were conducted  in 96-well V-bottom microplates  (1S- 
MVC-96 TC;  Linbro Chemical Company,  New  Haven,  Conn.) using a  methodology previously 
described (10).  Percent specific lysis was determined by using the following equation: 
experimental cpm  -  medium control cpm 
percent specific lysis =  100  x  maximum release cpm  -  medium control cpm" 
One lytic unit (LU) was defined as the number of effector cells required to cause 30% specific 
lysis.  Data is  displayed  both graphically  and in tabular form as percent cytotoxicity  observed at 
an  effector/target  cell  ratio  of  100/1,  and as LU/25 x 108  effector  cells.  In  cases  where 30% specific 
lysis  was not achieved even at  a relatively  high  effector/target  cell  ratio,  LU were determined  by 
graphical  interpolation. 
Results 
Target Cell Viral Genome Expression.  The virological  characterization  of 
all target cells  used in these studies is displayed in Tables II and III.  SFFV 
nonproducer fibroblast  cell  lines (1902  B  CI-4, 1902 B CI-6,  and SFFV-FRE) 
showed no virus  production as measured by XC, RT, and in  vivo  SFFV activity 
assays. In addition,  all  three SFFV nonproducers lacked cell  surface  expression 
of  viral  structural  antigens protein (p)10,  p12, p15, p30, or glycoprotein (gp)71 
as measured by antibody-dependent  complement-mediated cytolysis.  BALB/c 
3T3, 1902  B Cl-1  and KiSV-transformed K-BALB cells  were also  void  of viral 
genome expression. The SFFV  genome  contained in 1902 B  CI-4 cells  was 
effectively  rescued after  co-cultivation  with TNF and MBL-2 murine leukemia 
cells. Both 1902 B CI-4-R-MuLV,  and 1902 B CI-4-Mo-MuLV  were markedly 
positive  in  XC co-cultivation  assays.  24-h  tissue  culture  medium harvested from 
cultures of SFFV-rescued cell  lines,  contained high titers  of RT and in vivo 
SFFV activity.  1902  B C1-4-R-MuLV expressed p15,  p12,  gp71 at  the  cell  surface, 
and 1902  B CI-4-Mo-MuLV was positive  for  surface  expression of  gp71. BALB/c 
3T3 cells  infected  with R-MuLV,  F-MuLV,  and Mo-MuLV  tested  positive  for 
virus  production as measured in XC and RT assays,  and in  cytotoxicity  tests  for 
cell surface expression of viral  structural  antigens. The replication-defective 
MSV  genome contained in the K-BALB  cell  was rescued after  co-cultivation 
with TNF and MBL-2 leukemia cells.  Both K-BALB-Mo-MuLV  and K-BALB- 
R-MuLV  produced  high titers of both MuLV  and  transforming  virus (as 
measured by XC, RT, and in vitro  focus-formation  assays)  and tested  positive 
for  cell  surface  expression  of  gp71. 
LMC  Detection  of an  SFFV-Specific  Cell  Surface  Antigen.  Spleen  and 
inguinal  lymph  node  cells  from  BALB/c  mice  immunized  with  the  SFFV 
nonproducer  1902 B  C1-4, were stimulated  in a  5-day in vitro activation  with 
UV-irradiated,  1902 B C1-4 cells. Viable effector cells harvested from activated 
cultures  were then  tested for cytotoxic reactivity  against  a  battery of target 
cells.  Results of a  typical  experiment  are  displayed in  Fig.  1 A.  1902  B  C1-4- 
immune  lymphocytes were highly efficient in effecting the lysis of two SFFV 
nonproducer BALB/c 3T3 clones (1902 B C1-4 and 1902 B C1-6). BALB/c 3T3 cells 
and  BALB/c 3T3  fibroblasts  infected with  a  cloned  F-MuLV remained  unaf- 
fected. The data displayed in Fig. 1 A implied the existence of an antigen on the 22  SPLEEN  FOCUS-FORMING  VIRUS-SPECIFIC  ANTIGEN 
TABLE  II 
Virological Characterization of Target Cells 
Target cell 
XC Activity  In  Xeno-  vivo  MSV 
Tissue cul-  Target  RT ac-  tropic vi- 
ture su-  cells co-  tivity*  SFFV  activ-  rus pro- 
activ-  ity§  ductionl  I 
pernate  cultivated  ity$ 
PFU/ml  PFU/IO  4 
1902 B C1-4  0  0  0.04  0  0  <0.01 
1902 B C1-4-R-MuLV  0  131  39.7  350  0  0.01 
1902 B C1-4-Mo-MuLV  1,390  TNC¶  60.5  6  0  <0.01 
1902 B C1-6  0  0  0.01  0  0  <0.01 
SFFV-FRE  0  0  0.01  0  0  0.04 
FRE  0  0  0.01  nd**  0  <0.01 
MCDV-12  2,818  TNC  48.2  8  0  <0.01 
FLD-3  1,773  TNC  37.0  <10  0  <0.01 
BALB/c 3T3  0  0  0.67  nd  0  <0.01 
BALB/c 3T3-F-MuLV  2,265  TNC  68.3  nd  0  <0.01 
BALB/c 3T3-R-MuLV  70  TNC  29.2  nd  0  d0.01 
BALB/c 3T3-Mo-MuLV  490  TNC  46.2  nd  0  <0.01 
1902 B CI-1  0  0  0.07  nd  0  <0.01 
K-BALB  0  0  0.03  nd  0  0.04 
K-BALB-R-MuLV  1,050  TNC  40.4  nd  2,170  <0.01 
K-BALB-Mo-MuLV  5,550  TNC  41.4  nd  3,250  0.05 
ATS-Dog  nd  nd  nd  nd  nd  12.5 
NZB-Dog  nd  nd  nd  nd  nd  25.0 
* Expressed as cpm  x  10 -4 of [3H]thymidine triphosphate ([3H]TTP) incorporated by oligo dT 
poly rA template aliquot minus cpm of [3H]TTP incorporated by oligo dT poly dA template 
aliquot. 
$ Expressed  in  terms  of spleen  focus-forming units  (FFU)/ml  of target  cell  tissue  culture 
supernate. Only pertinent target cell fluids were assayed for in vivo SFFV activity. 
§ Expressed in terms of in vitro FFU/ml of target cell tissue culture supornate. 
[I Expressed in terms of RT activity of mink lung fibroblasts after 7-day culture in the presence of 
target cell tissue culture supernate. 
¶ TNC, too numerous to count. 
** nd, not done. 
surface of SFFV  nonproducer cells which w,as capable of provoking meaningful 
cell-mediated immune  reactivity. The fact that BALB/c 3T3 F-MuLV fibroblasts 
were  not  lysed by  1902  B  C1-4  immune  lymphocytes  suggested  that  this  cell 
surface antigen  was not coded for by the helper virus genome.  This suggestion 
was confirmed by results of subsequent  experimentation  displayed in Fig.  1 B. 
1902  B  C1-4-Mo-MuLV  and  1902  B  C1-4-R-MuLV  SFFV-rescued  targets  were 
effectively lysed by  SFFV  nonproducer-immune  activated  lymphocytes.  How- 
ever, BALB/c 3T3 cells productively infected with either R-MuLV or Mo-MuLV 
remained  unaffected. Therefore, the lysis of the SFFV-rescued cell lines was not 
due to cytotoxic reactivity directed against  an LLV-coded cell surface antigen. 
The  data  displayed  in  Fig.  1  along  with  the  observation  that  the  SFFV 
nonproducer cells lacked cell surface expression of type-, group-, or interspecies- 
specific viral structural  antigens,  indicated that  the antigen  detected by LMC 
was coded for solely by the SFFV  genome. 
It is interesting  to note that  both MCDV-12  (an RLV-induced leukemia  cell) STEVEN  GILLIS,  ANNE  E.  GILLIS,  AND  KENDALL  A.  SMITH 
TABLE  HI 
Target Cell Surface Expression of Virus Structural Proteins* 
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AKR  AKR  BALB  BALB  BALB  RLV  GLV GLV RLV  RLV  RLV  RLV  p60  RLV  Target cell  MuLV  MuLV  virus 2  virus 2  virus 2 
pl0  p30  pl0  p30  gp69/71  p12  p30  pl0  p12  p15  p30  pre-  gp69/71 
cursor 
1902 B C1-4  -$  ......... 
1902  B  CI-4-R-MuLV  .....  1,750  50  -  -  750 
1902  B  CI-4-Mo-MuLV  -  -  -  450  ...... 
1902 B CI-6  ........ 
SFFV-FRE  ......... 
FRE  ......... 
MCDV-12  ......  250  -  128  -  2,500 
FLD-3  ........  320 
BALB/c 3T3  ........... 
BALB/c 3T3-F-MuLV  -  -  -  450  ...... 
BALB/¢ 3T3-R-MuLV  -  -  -  1,350  ....  150 
BALB/c 3T3-Mo-MuLV  -  -  -  450  ..... 
1902  B  CI-I  ......... 
K-BALB  ........ 
K-BALB-P~MuLV  -  -  -  450  -  450  150  -  -  1,350 
K-BALB-Mo-MuLV  -  -  -  2,500  ..... 
* Expressed  as the reciprocal of the serum dilution which caused 20%  specific lysis in antibedy-dependent complement-mediated 
cytolysis assays. 
*  -,  No specific lysis observed. 
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FIG. i.  (A),  Cytotoxic reactivity  of 1902 B CI-4-immune, in vitro  activated spleen cells, 
directed against 1902 B CI-4 (i), 1902 B CI-6 (D), BALB/c 3T3 (Q), and BALB/c 3T3-F- 
MuLV  (O) target cells.  (B),  Cytotoxic reactivity  of  1902 B CI-4-immune, in vitro  activated 
spleen cells  directed against 1902 B CI-4-Mo-MuLV (D), 1902 B CI-4-R-MuLV (1),  MCDV- 
12 (O),  FLD-3 (©),  BALB/c 3T3-R-MuLV (A),  and BALB/c 3T3-Mo-MuLV  (~) target cells. 
and  FLD-3  (an  FLV-induced  erythroleukemia  cell)  were  effectively  lysed  by 
1902 B  C1-4 immune lymphocytes. This suggested the cell surface expression of 
the SFFV-specific antigen by in vivo transformed leukemia cells as well. 
The results of replicate  experiments  in which 1902 B  C1-4-immune,  in vitro 
activated lymphocytes were used as LMC effector cells are shown in Table IV. 
The data is presented in terms of LU/25  ×  l0  s effector cells,  and as the percent 
specific lysis observed at an effector/target cell ratio of 100/1.  Experimentation 24  SPLEEN  FOCUS-FORMING  VIRUS-SPECIFIC  ANTIGEN 
TABLE  IV 
Lysis of Target Cells by 1902 B-CI-4 Immune Spleen Cells 
Target cell 
Cytotoxicity at effec- 
LU/25 × 106 effec- tor/target cell ratio of 
tor cells 
100/1 
% 
1902 B C1-4  3,472  78 
1902 B C1-4-R-MuLV  313  88 
1902 B C1-4-Mo-MuLV  2,477  68 
1902 B C1-6  2,750  62 
SFFV-FRE  2,500  72 
FRE  0.5  12 
MCDV-12  41.7  25 
FLD-3  312.5  32 
BALB/c 3T3  1.8  4 
BALB/c 3T3-F-MuLV  6.3  8 
BALB/c 3T3-R-MuLV  0.6  7 
BALB/c 3T3-Mo-MuLV  6.7  9 
1902 B Cl-1  7.1  11 
K-BALB  0.5  8 
K-BALB-R-MuLV  5.0  6 
K-BALB-Mo-MuLV  <0.01  4 
BALB/c thymocytes  <0.01  6 
displayed in Table IV emphasizes that the cytotoxic reactivity of 1902 B C1-4- 
immune lymphocytes appears to be directed only against target cells containing 
the SFFV genome. 1902 B C1-4 and 1902 B  C1-6 cells, along with the SFFV 
rescued targets, were quite susceptible to lysis by 1902 B C1-4 activated effector 
cells.  Once more, BALB/c 3T3 (both the parent BALB/c 3T3 population and the 
1902 B  CI-1 cloned 3T3  cells)  and  3T3  MuLV-infected target cells were not 
effectively  lysed by SFFV nonproducer immune lymphocytes. It is important to 
note that both K-BALB cells and the KiSV-rescued, K-BALB-Mo-MuLV  and K- 
BALB-R-MuLV  targets were not lysed by SFFV nonproducer-activated spleen 
cells.  The lack of cytotoxic reactivity against these cells further demonstrated 
that the antigen present on the 1902 B C1-4 SFFV nonproducer was not coded 
for by a  helper virus genome, nor was it shared by MSV genome-containing 
target cells.  Data displayed in Table IV also demonstrated that  1902 B C1-4 
immune effector cells were capable of killing the xenogeneic SFFV-FRE cell. 
This observation emphasizes the SFFV-specific nature of the antigen in ques- 
tion and furthermore, provides indirect evidence that the antigen in question is 
not coded for by endogenous murine genome(s) activated in the BALB/c  3T3 
cells by the SFFV genome. 
Discussion 
The results of these studies indicate that the SFFV genome codes for a cell 
surface antigen which is capable of provoking an antigen-specific cell-mediated 
immune response. The antigen was detected on the surface of cloned BALB/c 
3T3 and FRE fibroblasts which contained the SFFV genome, free of replicating 
LLV. The SFFV nonproducer fibroblasts were void of cell surface expression of 
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mediated cytolysis assays using monospecific antisera raised against purified 
murine ecotropic and xenotropic structural polypeptides. Normal BALB/c 3T3 
fibroblasts and BALB/c 3T3 cells infected with three types of helper LLV were 
not susceptible to lysis by SFFV nonproducer-immune  lymphocytes. Based upon 
these observations, it is reasonable to assume that the antigen detected in these 
LMC  experiments is  not  coded for by genetic information contained in  the 
helper component of FLV  and  represents a  true  SFFV-specific cell  surface 
antigen. 
Several nonproducer-specific antigens have been investigated in experimen- 
tal sarcoma and leukemia virus systems. However, most reported nonproducer 
TASAs have been confirmed serologically. The existence of such humorally 
defined TASAs remains a controversial subject, due to reports claiming that the 
antigens detected are simply viral structural proteins present at the cell surface. 
Cats infected with feline leukemia virus (FeLV)  contain in their sera anti- 
bodies specific for an antigen present on the surface of FeLV-transformed cat 
cells (19). Antisera harvested from FeLV-infected cats retains its specificity and 
affinity for the feline leukemia cell surface, even aider absorption with FeLV 
structural proteins gp70 and p30 (20). Furthermore, humoral reactivity against 
this serologically detected feline-oncornavirus-associated cell membrane anti- 
gen (FOCMA) has been shown to positively correlate with the natural resist- 
ance of cats to FeLV-induced leukemia or sarcoma (21). Data intimating that 
FOCMA expression may be the result of sarcoma virus genetic sequences was 
reported in  studies detailing FOCMA cell surface expression on replication- 
defective FeLV-transformed mink cells  (22). Whether or not  FOCMA  truly 
represents a  cell surface neoantigen distinct from virion structural proteins 
remains open to question.  Recently, Ruscetti and Parks  (23), using immune 
precipitation of radiolabeled cell membranes and polyacrylamide gel electro- 
phoresis presented evidence indicating that anti-FOCMA immune reactivity 
may indeed be directed against a class of 85,000 mol wt proteins which contain 
determinants of the major FeLV glycoprotein. 
A  similar  antigen  present  on  the  surface of cells  transformed by  Gross 
leukemia virus (GLV) has also been recently characterized. Antibody directed 
against the Gross cell surface antigen (GCSA) has been traditionally prepared 
by  immunization of C57B1/6 mice with  the  transplanted  AKR  spontaneous 
leukemia  (K-36) (24). Anti-GCSA  antibody  has  been  found to  be  cytotoxic 
against cells infected with GLV and absorbed by the normal lymphoid tissues of 
mice with high incidences of spontaneous leukemia (24, 25). Investigators using 
immunoelectron microscopy have determined that anti-GCSA antisera does not 
bind  to  portions  of GLV-transformed lymphoma cell  membranes that  are 
associated with budding virions (26). This observation prompted the suggestion 
that GCSA was not a structural component of GLV. However, two groups have 
simultaneously reported (in radioimmunoprecipitation studies) that the GCSA 
complex is actually composed of glycosylated precursors of MuLV core proteins 
which contain antigenic determinants specific for p30, p12, and pl0 (27, 28). 
In  the  Mo-MuLV  system,  a  similar  nonvirion  TASA  has  been  detected 
(Moloney cell-surface antigen; MCSA) using sera of syngeneic mice immunized 
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has been found to contain virus-neutralizing antibodies which represent reactiv- 
ity against gp71, the major envelope glycoprotein. However, virus-neutralizing 
activity  could be  removed by  absorption  either  with  cells  which expressed 
surface concentrations of gp71 or with intact Mo-MuLV. This treatment had 
little effect on the antisera's cytotoxicity directed against lymphoma cells (30). 
Recently, MCSA activity (tool wt 110,000) has been physically separated from 
Mo-MuLV structural proteins by concanavalin A affinity chromatography, gel 
filtration,  and velocity centrifugation (30). These results suggest that lVICSA 
indeed represents a  neoantigen separate from virion structural proteins. An 
approach employing virus-transformed nonproducer tumor cells, similar to that 
used in the present studies,  would lend further evidence in  support of this 
interpretation. 
Greenberger et al.  (31) have demonstrated (using immunoelectron micros- 
copy) a nonvirion TASA expressed on the surface of nonproducer K-BALB cells 
which could not be  detected on  the  parent  BALB/c  3T3  cell  line.  Because 
administration of this K-BALB antigen-specific antisera to normal mice did not 
protect against subsequent tumor challenge, these investigators concluded that 
the neoantigen present on the K-BALB cell did not function as a tumor-specific 
transplantation  antigen.  Recently,  we  reported  the  detection  of  a  similar 
nonvirion  K-BALB-specific  antigen  using  the  techniques  of secondary  and 
tertiary MTLC followed by LMC.  Transfer of in vitro activated lymphocytes 
along with a lethal challenge of K-BALB cells to normal BALB/c mice mediated 
almost complete protection against  subsequent K-BALB tumor development 
(32). These findings suggest that a nonvirion antigen present on K-BALB cells 
does function as  a  TSTA.  Whether  or not this  antigen is  coded for by the 
replication-defective portion of the  KiSV  genome has  not been established. 
However, this TSTA is not present on parent BALB/c 3T3 cells as detected by 
LMC  (K.  A.  Smith,  IV[. M.  Ferm,  S.  Gillis,  and  A.  E.  Gillis,  unpublished 
observations). 
A common cell surface antigen (FMR) has been described on leukemia cells 
induced in vivo by FLV, RLV, and Mo-MuLV. Initial studies reporting cross- 
reactivity  between  all  three  virally-induced  leukemias  have  recently  been 
questioned by results showing that cells induced by Mo-MuLV were antigeni- 
cally distinct from those induced by FLV and RLV (33). These data imply that 
such a  serologically detected antigen common only to  Friend  and Rauscher 
leukemias may have determinants coded for by the SFFV genome. Regardless of 
the cross-reactivity of antigenic determinants detected by anti-FMR antisera, 
the  nonvirion nature  of these determinants has not been thoroughly estab- 
lished. It has been shown that anti-FLV antisera remain cytotoxic against FLV- 
transformed spleen cells despite exhaustive absorption with purified FLV (34). 
However, the demonstration that the cytotoxic reactivity of anti-FMR antisera 
could  be  removed  by  absorption  with  disrupted  virus  suggests  that  FMR 
antibody reactivity may be directed against internal virion proteins (6). Despite 
these results, the observation that SFFV-immune lymphocytes mediated the 
lysis of FLV and RLV transformed leukemia cells suggests that some portion of 
classically defined FMR antigenic determinants may be ceded for by SFFV gene 
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The  SFFV  genome as  it  exists  in  the  fibroblast nonproducer target cells 
studied  in  these  investigations  has  recently  been  analyzed  by  molecular 
hybridization. The genome appears to be a recombinant between a portion of 
the F-MuLV genome and RNA sequences that are highly related (hybridizable) 
to three separate strains of murine xenotropic virus (11). Further investigation 
has confirmed that the recombinational event between ecotropic and xenotropic 
virus  sequences  (responsible  for the  elaboration of SFFV  genome) occurred 
somewhere in the envelope region of the xenotropic viral genome (35). It is 
plausible that the specific cell surface antigen described in this report might be 
coded  for  by  the  xenotropic  viral  information contained  within  the  SFFV 
genome. It would appear unlikely that the ecotropic sequences of the SFFV 
genome were responsible for coding for the SFFV antigen, in that BALB/c 3T3 
cells productively infected with three types of ecotropic helper virus were not 
susceptible to lysis by SFFV nonproducer-immune  lymphocytes. 
Recently, Bernstein et al.  (8) in radioimmunoassay (RIA) studies of SFFV- 
containing murine and rat fibroblasts has determined that SFFV nonproducers 
contain high levels of cytosol p15, whereas the remaining gag-gene coded core 
proteins  and the  envelope glycoprotein gp71 were not present  in  detectable 
concentrations. Similar RIA studies of the SFFV nonproducer cells used in this 
report  confirmed the  cytosol presence of both  p15  and  p12  (D.  H.  Troxler, 
personal communication). These results intimate that the portion of ecotropic 
virus which remains complexed with the xenotropic sequences of SFFV RNA 
represent early gag-gene regions. 
It is important to note that the 15,000 mol wt protein detected in the above- 
mentioned RIA studies was not further characterized as the core (C) polypeptide 
p(15)C or the envelope (E) polypeptide p(15)E. The localization of a 15,000 mol 
wt protein [p(15)E] on the surface on intact C-type virus particles was originally 
described in neutralization experiments using anti-p(15)E antisera (36). Fur- 
thermore, p(15)E has been isolated from virus-infected  cells in stable association 
with gp71 as a common polypeptide precursor (37). Although specific chemical 
differences between p(15)E  and p(15)C have not been detailed, the antigenic 
characteristics of both molecules have been described, p(15)E appears to carry 
antigenic determinants with strong interspecies specificity as observed by the 
neutralization of FeLV and several murine xenotropic viruses by anti-FLV- 
p(15)E  antisera (38). This observation is especially intriguing in light of the 
recently defined genetic composition of the SFFV genome as a recombination of 
ecotropic sequences into the envelope region of xenotropic MuLV. 
Although one cannot rule out the possibility that the antigen described in 
these studies is a gag-gene-coded polypeptide, the observation that the p15 and 
p12 positive K°BALB R-MuLV target cell (Table III) was not lysed by 1902 B 
C1-4-immune spleen cells  (Table  IV)  further supports  the  nonvirion SFFVo 
specific  nature  of the  antigen  detected.  It  is  possible,  however,  that  the 
antibody-dependent, complement-mediated cytolysis assay used in virological 
characterizations  was  not  sensitive  enough  to  detect  extremely small  cell 
surface concentrations of viral structural proteins. Perhaps an isotopic antiglob- 
ulin binding assay such as that described by Ruscetti and Parks (23) would be a 
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use of radiolabeled target cell membranes in radioimmunoprecipitation  compet- 
itive RIA studies might provide the most accurate means of determining the 
cell surface viral antigen expression of SFFV nonproducer cells. 
Several analogies have been consistently drawn between the MSV and SFFV 
genome. Both are replication-defective and require rescue by tropic LLV. Both 
genomes are accepted as being responsible for the malignant transformation 
event in vivo.  Studies conducted in this report (Table IV) indicate that a cell 
surface antigen coded expressly by SFFV genetic information is not shared by 
MSV-transformed fibroblasts, regardless of their capacity to produce infectious 
transforming virus. The lack of cross-reactive antigenicity in MSV and SFFV 
nonproducer cells is an observation which is understandable in light of recent 
hybridization investigations, indicating that little if any genetic information is 
common to both SFFV and MSV genomes. However, the detection of cell surface 
antigens by LMC on KiSV and SFFV replication-defective nonproducer cells 
suggests  that  nonvirion  cell  surface  antigens  may be  coded for by  genetic 
information intimately associated with those genes responsible for malignant 
transformation. 
Summary 
The existence of a nonvirion tumor-associated cell surface antigen (TASA) on 
cells transformed with Friend (FLV) on Rauscher (RLV) leukemia virus has 
been difficult to demonstrate. Antisera raised against classically defined Friend- 
Moloney-Rauscher antigenic determinants have been shown to react with virus 
structural proteins coded for by genetic information contained in the lymphatic 
leukemia or helper (LLV) virus genome. The recent development of nontrans- 
formed fibroblast cell lines which contain the replication-defective spleen focus- 
forming virus (SFFV) genome, free of replicating LLV, has allowed investiga- 
tion of an  SFFV-specific antigen.  We have applied the techniques of mixed 
tumor-lymphocyte  culture stimulation followed by lymphocyte-mediated  cytol- 
ysis assays to search for the cell surface expression of an antigen coded expressly 
by SFFV genetic information. 
SFFV nonproducer-immune, in vitro activated spleen cells were capable of 
effecting the lysis of SFFV-containing BALB/c 3T3 and Fischer rat epithelial, 
cloned cell lines. Normal BALB/c 3T3 and BALB/c 3T3 cells infected with three 
types  of ecotropic  LLV  were  unaffected.  Syngeneic FLV  and  RLV-induced 
murine leukemia cells were also killed by SFFV nonproducer-immune  lympho- 
cytes. In addition, Kirsten sarcoma virus-transformed, replication-defective  and 
replication-rescued BALB/c  3T3  fibroblasts  were  not  susceptible  to  SFFV 
antigen-directed cytolysis. Antibody-dependent complement-mediated  cytolysis 
assays using monospecific goat antisera confirmed that  SFFV  nonproducers 
lacked cell surface expression of virion structural proteins. 
These observations suggest that the antigen detected in LMC experiments 
was not coded for by genetic information contained in the helper component of 
FLV,  and that it represents a  true SFFV-specific cell surface antigen. Based 
upon the recent molecular evaluation of the SFFV genome as consisting of both 
xenotropic and ecotropic virus sequences, it appears reasonable that xenotropic 
genetic information may be  responsible for expression of the  SFFV-specific STEVEN  GILLIS,  ANNE  E.  GILLIS,  AND  KENDALL  A.  SMITH  29 
antigen.  Since the replication-defective SFFV genome is also responsible for the 
malignant transformation  associated with  FLV-induced  erythroleukemia,  one 
might  postulate  that  gene  sequences  capable of programming transformation 
may also code for the TASA detected in these studies. 
The authors gratefully acknowledge  Doctors D.  H. Troxler and E.  M.  Scolnick  (Laboratory of 
Tumor Virus Genetics, National Cancer Institute, Bethesda, Md.) for providing many of the cell 
lines used in these studies,  and Dr. Richard A. Steeves for conducting in vivo SFFV assays. We 
also wish to thank Ms.  Susan  Kennedy,  Ms.  Mary Ferm, and Ms.  Rachel  Stocking  for their 
invaluable assistance in performing virological  characterizations of all target cells tested. We 
also wish to thank Ms. Linda Waidlick for her expert editorial and secretarial assistance. 
Received for publication 15 February 1978. 
References 
1.  Fefer,  A.,  J.  L.  McCoy,  and  J.  P.  Glynn.  1967. Antigenicity  of a  virus-induced 
murine sarcoma (Moloney). Cancer Res. 27:962. 
2.  Geering,  G.,  L. J.  Old,  and E. A.  Boyse.  1966. Antigens of leukemias induced by 
naturally occurring murine leukemia virus: their relation to the antigens of Gross 
virus and other murine leukemia viruses. J. Exp. Med. 124:753. 
3.  Chang,  K.  S.  S.,  L.  W.  Law,  and  E.  Appella.  1975. Distinction  between  tumor- 
specific transplantation  antigen  and  virion antigens  in  solubilized products from 
membranes of virus-induced leukemic cells. Int. J. Cancer. 15:483. 
4.  Fieldsteel, A. H., P. J. Dawson, and C. Kurahara.  1973. Tumor-specific transplan- 
tation antigens in reticulum cell sarcomas and lymphomas induced by the Friend 
virus complex. Cancer Res. 33:551. 
5.  Lilly, F., and R. A. Steeves. 1973. B-tropic Friend virus: a host range pseudotype of 
spleen focus-forming virus. Virology.  55:363. 
6.  Friedman, M., F. Lilly, and S. G. Nathenson.  1974. Cell surface antigen induced by 
Friend murine leukemia virus is also in the virion. J. Virol.  14:1126. 
7.  Troxler, D. H., W.  P.  Parks,  W.  C. Vass, and E. M.  Scolnick.  1977. Isolation of a 
fibroblast nonproducer cell line containing the  Friend  strain  of the  spleen focus- 
forming virus. Virology.  76:602. 
8.  Bernstein,  A.,  T.  W.  Mak,  and J.  R.  Stephenson.  1977. The Friend virus genome: 
evidence for the stable association of MuLV sequences and sequences involved in 
erythroleukemic transformation. Cell.  12:287. 
9.  Plata,  F.,  H.  R.  MacDonald,  and H. D.  Engers.  1976. Characterization of effector 
lymphocytes associated  with  immunity  to  murine  sarcoma virus  (MSV)  induced 
tumors. J. Immunol. 117:52. 
10.  Gillis,  S.,  and  K.  A.  Smith.  1977. In vitro generation  of tumor-specific cytotoxic 
lymphocytes.  Secondary  allogeneic  mixed  tumor  lymphocytic  culture  of normal 
murine spleen cells. J. Exp. Med. 146:468. 
11.  Troxler, D. H., J. K. Boyers, W. P. Parks, and E. M. Scolnick. 1977. Friend strain of 
spleen  focus-forming virus:  a  recombinant between  mouse type C  ecotropic viral 
sequences and sequences related to xenotropic virus. J. Virol. 22:361. 
12.  Fredrickson,  T.  N.,  J.  LoBue,  P.  A.  Alexander,  E.  F.  Schultz,  and A.  S.  Gordon. 
1972.  A  transplantable  leukemia  from mice  inoculated  with  Rauscher  leukemia 
virus. J. Natl. Cancer Inst. 48:1597. 
13.  Stephenson, J. R., and S. A. Aaronson. 1972. Antigenic properties of murine sarcoma 
virus-transformed BALB 3T3 nonproducer cells. J. Exp. Med. 135:503. 
14.  Abrell, J. W., and R. C. Gallo. 1973. Purification, characterization, and comparison 30  SPLEEN  FOCUS-FORMING VIRUS-SPECIFIC  ANTIGEN 
of the DNA polymerases from two primate RNA tumor viruses. J. Virol.  12:431. 
15.  Rowe, W.  P.,  W.  E.  Pugh,  and J.  W.  Hartley.  1970. Plaque  assay techniques for 
murine leukemia viruses. Virology. 42:1136. 
16.  Aaronson,  S.  A.,  J.  L.  Jainchill,  G.  J.  Todaro.  1970. Murine  sarcoma  virus 
transformation of BALB/c 3T3 cells: lack of dependence on murine leukemia virus. 
Proc. Natl. Acad. Sci.  U. S. A. 66:1236. 
17.  Peebles, P. T. 1977. An in vitro focus-induction assay for xenotropic MuLV, FeLV-C 
and the feline-primate viruses. Virology.  76:602. 
18.  Axelrad,  A.  A.,  and R.  A.  Steeves.  1964. Assay for Friend leukemia virus:  rapid 
quantitative  method  based  on  enumeration  of macroscopic  spleen  foci  in  mice. 
Virology. 24:513. 
19.  Essex,  M.,  C.  T.  Klein,  S.  P.  Snyder,  and J.  B.  Harold.  1971. Antibody to feline 
oncornavirus associated cell membrane antigen  in neonatal  cats. Int.  J.  Cancer. 
8:384. 
20.  Stephenson, J. R., M. Essex, S. Hino, W. D. Hardy, and S. A. Aaronsen. 1977. Feline 
oncornavirus-associated  cell-membrane  antigen  (FOCMA):  distinction  between 
FOCMA and the major virion glycoprotein. Proc. Natl. Acad. Sci.  U. S. A. 74:1219. 
21.  Essex,  M.,  A.  Sliski,  S.  M.  Cotter,  R.  M.  Jakowski,  and  W.  D.  Hardy.  1975. 
Immunoserveillance of naturally occurring feline leukemias. Science (Wash. D. C.). 
190:790. 
22.  Sliski,  A.  H.,  M.  Essex,  C.  Meyer,  and  G.  Todaro.  1977. Feline  oncornavirus- 
associated  cell  membrane  antigen:  expression  in  transformed nonproducer  mink 
cells. Science {Wash. D. C.). 196:1336. 
23.  Ruscetti, S.  K., and W. P. Parks.  1977. Characterization of a feline luekemia viral 
cell membrane antigen reactive with feline sera. J. Immunol. 119:2194. 
24.  Old,  L.  J.,  E.  A.  Boyse, and E.  Stockart.  1965. The G  (Gross) leukemia antigen. 
Cancer Res. 25:813. 
25.  Kawashima, K., H. Ikeda, J. W. Hartley, E. Stockart, W. P. Rowe, and L. J. Old. 
1976. Changes in expression of murine leukemia virus antigens and production of 
xenotropic virus in the late pre-leukemia period in AKR mice. Proc. Natl. Acad. 
Sci.  U. S. A. 73:4680. 
26.  Aoki, T., E. A. Boyse, L. J.  Old, E.  Dellarven, U.  Hammerling, and H. A. Wood. 
1970. G  (Gross) and H-2 cell surface antigens: location on Gross leukemia cells by 
electron microscopy with visually labeled antibody. Proc. Natl. Acad. Sci.  U. S. A. 
65:569. 
27.  Snyder,  H. W.,  E. Stockart,  and E.  Fleissner.  1977. Characterization of molecular 
species carrying Gross cell surface antigen. J. Virol. 23:302. 
28.  Ledbetter,  J.,  and  R.  C.  Nowinski.  1977. Identification of the  Gross cell  surface 
antigen associated with murine leukemia virus-infected cells. J. Virol. 23:315. 
29.  Klein,  G., E.  Klein,  and G. Haughton.  1966. Variation of antigenic characteristics 
between different mouse lymphoma induced by Moloney virus. J. Natl. Cancer Inst. 
36:607. 
30.  Siegert, W., E. M.  Fenyo, and G. Klein.  1977. Separation of the Moloney leukemia 
virus-determined cell surface antigen (MCSA) from known virion proteins associated 
with the cell membrane. Int. J. Cancer. 20:75. 
31.  Greenberger, J. S., J. R. Stephenson, T. Aoki, and S. A. Aaronson. 1974. Cell-surface 
antigens of murine sarcoma-virus-transformed nonproducer cells: further evidence 
for lack of transplantation immunity. Int. J. Cancer. 14:145. 
32.  Smith, K. A., M. M. Ferm, S. Gillis, and A. E. Gillis. 1977. The detection of a tumor- 
specific transplantation antigen on nonvirus-producer cells by cell mediated cytotox- 
icity.  In Comparative Leukemia Research,  1977. Elsevier Nederland,  Amsterdam, 
The Netherlands. In press. STEVEN  GILLIS,  ANNE  E.  GILLIS,  AND  KENDALL  A.  SMITH  31 
33.  Fenyo,  E.  M.,  and  G.  Klein.  1976. Independence of Moloney virus-induced cell- 
surface antigen and membrane-associated virion antigens in immunoselected lym- 
phoma sublines. Nature  (Lond.).  260:355. 
34.  Steeves, R. A. 1976. Cellular antigen of Friend virus-induced leukemias. Cancer Res. 
28:338. 
35.  Troxler, D.  H., D.  Lowry, R.  Howk, H.  Young, and E.  M.  Scolnick.  1977. Friend 
strain of spleen focus-forming virus is a recombinant between ecotropic murine type 
C virus and the envelope gene region of xenotropic type C virus. Proc. Natl. Acad. 
Sci. U. S. A. 74:4671. 
36.  Schafer, W.,  G.  Hunsmann,  V.  Moennig,  F.  DeNoronha,  D.  P.  Bolognesi, R.  W. 
Green, and G. Huper. 1975. Polypeptides of mammalian oncornaviruses. II. Charac- 
terization of a murine leukemia virus polypeptide (p15) bearing interspecies reactiv- 
ity. Virology. 63:48. 
37.  Famulari, N. G., D. L. Buchhagen, H. D. Klenk, and E. Fleissner. 1976. Presence of 
murine leukemia virus envelope proteins gp70 and p(15)E in a common polyprotein 
of infected cells. J. Virol. 20:501. 
38.  Fischinger, P. J., Schafer, W., and D. P. Bolognesi. 1976. Neutralization of homolo- 
gous  and  heterologous oncornaviruses by  antisera  against  the  p15(E)  and  gp71 
polypeptides of Friend murine leukemia virus. Virology.  71:169. 